StreetInsider.com News Articles

Zoetis Inc. (ZTS) PT Lowered to $99 at Morgan Stanley

Wed, 22 Jul 2026 08:28:58 -0400

Morgan Stanley analyst Erin Wright lowered the price target on Zoetis Inc. (NYSE: ZTS) to $99.00 (from $115.00) while maintaining a Overweight rating.

Zoetis launches feline osteoarthritis drug in Canada and EU

Wed, 22 Jul 2026 07:30:59 -0400

Zoetis Inc. (NYSE: ZTS) has launched Portela (relfovetmab) in Canada and European Union member states, a monoclonal antibody therapy for cats with osteoarthritis pain.

Portela is administered as a single subcutaneous injection once every three months. The company claims it is the first long-acting anti-nerve growth factor monoclonal antibody therapy for cats. Zoetis says the drug demonstrated effectiveness in alleviating osteoarthritis pain in a nine-month European field study, with improvements observed from as early as three days after the first injection.

The drug works by binding to nerve growth factor, a mediator of pain and inflammation, at what the company describes as

Zoetis Launches Portela® (relfovetmab) in Canada and the European Union

Wed, 22 Jul 2026 07:30:00 -0400

First long-acting anti-NGF monoclonal antibody therapy for cats offers three months of osteoarthritis pain relief with a single injection

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc. (NYSE: ZTS) today announced the commercial launch of Portela® (relfovetmab) in Canada and the European Union (EU) member states. Portela is the first long-acting anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy for cats, designed to alleviate pain associated with osteoarthritis (OA) for up to three months with a single subcutaneous injection. Backed by nearly a decade of science and research, Portela demonstrated effectiveness in alleviating OA pain in

Zoetis Launches Portela® (relfovetmab) in Canada and the European Union

Wed, 22 Jul 2026 07:30:00 -0400

First long-acting anti-NGF monoclonal antibody therapy for cats offers three months of osteoarthritis pain relief with a single injection

Zoetis Launches Portela® (relfovetmab) in Canada and the European Union

Wed, 22 Jul 2026 07:30:00 -0400

First long-acting anti-NGF monoclonal antibody therapy for cats offers three months of osteoarthritis pain relief with a single injection

Zoetis Launches Portela® (relfovetmab) in Canada and the European Union

Wed, 22 Jul 2026 07:30:00 -0400

First long-acting anti-NGF monoclonal antibody therapy for cats offers three months of osteoarthritis pain relief with a single injection

Zoetis Launches Portela® (relfovetmab) in Canada and the European Union

Wed, 22 Jul 2026 07:30:00 -0400

First long-acting anti-NGF monoclonal antibody therapy for cats offers three months of osteoarthritis pain relief with a single injection

Zoetis Launches Portela® (relfovetmab) in Canada and the European Union

Wed, 22 Jul 2026 07:30:00 -0400

First long-acting anti-NGF monoclonal antibody therapy for cats offers three months of osteoarthritis pain relief with a single injection

Zoetis Launches Portela® (relfovetmab) in Canada and the European Union

Wed, 22 Jul 2026 07:30:00 -0400

First long-acting anti-NGF monoclonal antibody therapy for cats offers three months of osteoarthritis pain relief with a single injection

Zoetis Launches Portela® (relfovetmab) in Canada and the European Union

Wed, 22 Jul 2026 07:30:00 -0400

First long-acting anti-NGF monoclonal antibody therapy for cats offers three months of osteoarthritis pain relief with a single injection

Zoetis launches dog osteoarthritis drug in Canada and EU

Wed, 15 Jul 2026 08:31:02 -0400

Zoetis Inc. (NYSE: ZTS) has launched Lenivia (izenivetmab injection), a monoclonal antibody therapy for osteoarthritis pain in dogs, in Canada and European Union member states, according to a company press release.

Lenivia is administered as a single subcutaneous injection once every three months. The therapy targets nerve growth factor, a mediator of pain and inflammation. Zoetis states the drug binds to a different site on nerve growth factor compared to other anti-NGF monoclonal antibodies already on the market.

A nine-month European field study cited by the company showed a sustained reduction in pain, with effects observed from as early as seven days

Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union

Wed, 15 Jul 2026 08:30:00 -0400

Up to 40% of dogs may have radiographic osteoarthritis - New long-acting monoclonal antibody therapy offers three months of osteoarthritis pain relief for dogs with a single injection

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Zoetis Inc. (NYSE: ZTS) today announced that it has recently launched Lenivia® (izenivetmab injection) in Canada and the European Union (EU) member states – a new long-acting monoclonal antibody (mAb) therapy designed to deliver up to three months of osteoarthritis (OA) pain management with a single subcutaneous injection. Backed by a decade of science and research, Lenivia demonstrated a sustained reduction in

Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union

Wed, 15 Jul 2026 08:30:00 -0400

Up to 40% of dogs may have radiographic osteoarthritis - New long-acting monoclonal antibody therapy offers three months of osteoarthritis pain relief for dogs with a single injection

Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union

Wed, 15 Jul 2026 08:30:00 -0400

Up to 40% of dogs may have radiographic osteoarthritis - New long-acting monoclonal antibody therapy offers three months of osteoarthritis pain relief for dogs with a single injection

Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union

Wed, 15 Jul 2026 08:30:00 -0400

Up to 40% of dogs may have radiographic osteoarthritis - New long-acting monoclonal antibody therapy offers three months of osteoarthritis pain relief for dogs with a single injection

Form 4 Zoetis Inc. For: Jul 10 Filed by: Lagano Roxanne